Halozyme Therapeutics has entered a global collaboration with GSK to use its ENHANZE® drug delivery technology for subcutaneous administration of oncology drugs, including antibody drug conjugates (ADCs). This partnership marks the first time ENHANZE® will be applied to ADCs, potentially improving treatment safety and convenience. GSK will pay upfront and milestone fees to Halozyme, which will also earn royalties on sales. The first clinical trial under this agreement is expected to begin in 2026, aiming to reduce treatment burden for cancer patients.
UBS maintains a neutral rating on GSK ahead of its Q2 results, focusing on CEO Luke Miels' upcoming strategy update. UBS expects little market reaction to the earnings, highlighting concerns over a £4 billion gap between GSK's sales target and foreca...
UBS maintains a neutral rating on GSK ahead of its Q2 results and a strategy update from new CEO Luke Miels, focusing on whether he can deliver GSK's target of over £40 billion in risk-adjusted sales by 2031. UBS forecasts slightly below consensus fo...
